Apnea of prematurity: What we don’t know
However, although researchers agree on the above facts, that doesn’t necessarily mean that everything about apnea of prematurity is clear and well understood.
According to the Apnea-of-Prematurity Group’s statement referenced above, “there is no consensus about the duration of apnea that should be considered pathologic.” There’s also “no agreement” about what “constitutes an important apnea event.” And even though apnea events respond to drugs and physical interventions, it isn’t yet known whether these interventions “have any long-term effects.”
“Clinicians often use off-label drugs that have been approved for gastroesophageal reflux disease, which is common in premature infants, with the belief that such treatments also have an impact on AOP, although this link has never been demonstrated,” the group adds.
However, these experts admit that, despite these uncertainties about treating apnea of prematurity, “providing no treatment when an infant stops breathing in the NICU is not an option.”
They add: “The immediate and irresistible urge to respond to apnea is based partly on the uncertainty about exactly what causes the apneic episode and whether the unknown causative factor might also harm the brain or other systems and produce a long-term effect on neurodevelopment.”
So, even given the relative common nature of apnea of prematurity and its tendency to resolve itself with age, sleep apnea in premature babies remains a source of concern for many pediatric physicians who are unsure about long-term effects of treatments.
This blog post contains general information about medical conditions and potential treatments. It is not medical advice. If you have any medical questions, please consult your doctor.